Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: Features, incidence, identification, and treatment

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 3, 2008, Pages 282-285

  Miesbach, Wolfgang ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Malignancy; Thrombosis; Treatment

Indexed keywords

CARDIOLIPIN ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ASHERSON SYNDROME; AUTOIMMUNE DISEASE; BREAST CARCINOMA; CANCER INCIDENCE; CLINICAL FEATURE; COLON CARCINOMA; COMORBIDITY; DISEASE ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER CARCINOMA; LUNG CARCINOMA; LYMPHATIC LEUKEMIA; LYMPHOMA; MONOCYTIC LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOLID TUMOR; STOMACH CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; INCIDENCE; MULTIPLE ORGAN FAILURE; NEOPLASMS; PARANEOPLASTIC SYNDROMES; THROMBOPHILIA; THROMBOSIS;

EID: 50249102193     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1082272     Document Type: Article

References (40)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique Medical de L'Hotel Dieu de Paris. Vol. 3. London, United Kingdom: The New Sydenham Society; 1865;94
2. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based control study. Arch Intern Med 2000;160:809-815
3. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-145
4. Blom JW, Doggen CJ, Osanto S. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722
5. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410
6. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 2000;342:1953-1958
7. Monreal M, Fernandez-Llamazares J, Perandreu J, et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997;78:1316-1318
8. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295-306
9. Asherson RA. Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun 2000;15:117-122
10. Asherson RA, Cervera R. Antiphospholipid antibodies and malignancies. In: Shoenfeld Y, ed. Cancer and Autoimmunity. Amsterdam, The Netherlands: Elsevier; 2000:93-102
11. Kazmierczak M, Lewandowski K, Wojtukiewicz MZ. Cancer proagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis 2005;16:543-547
12. Langer F, Eifrig B, Hegewich-Becker S. Complicated antiphospholipid syndrome. Dtsch Med Wochenschr 2002;127:1458-1462
13. Schreiber DP, Kepp DS. Axillary subclavian vein thrombosis following combination chemotherapy and radiation therapy in lymphoma. Int J Radiat Oncol Biol Phys 1986;12:391-395
14. Ruffatti A, Avorsa A, Del Ross T, et al. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome. J Rheumatol 1994;21:2162-2163
15. Kozlowski CL, Johnson MJ, Gorst DW, et al. Lung cancer, immune thrombocytopenia and the lupus inhibitor. Postgrad Med J 1987;63:793-795
16. Papagiannis A, Cooper A, Bans J. Pulmonary embolism and lupus anticoagulant in a woman with renal cell carcinoma. J Urol 1994;152:941-942
17. Park CJ, Gho HI, Kim SI. A study of changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma. J Korean Med Sci 1991;6:1-6
18. Asherson RA, D'Cruz D. Vascular occlusions in a patient with low positive antiphospholipid antibodies and subsequent development of breast carcinoma: a diagnostic dilemma. Clin Rheumatol 2007;26:1531-1533
19. Stasi R, Stipa E, Masi M, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. Thromb Haemost 1993;70:568-572
20. Athale UH, Chan AK. Thrombosis in children with lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 2003;111:321-327
21. Mouas H, Lortholary O, Eclache V, et al. Antiphospholipid syndrome during acute monocytic leukemia. Eur J Haematol 1994;53:59-60
22. Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid syndrome. J Pediatr Hematol Oncol 2004;26:327-330
23. Zuckerman E, Toubi E, Golan T, et al. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 1995;72:447-451
24. Pusterla S, Previtali S, Marziali S, et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5:341-346
25. Genvresse I, Lüftner D, Späth-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anfi-β2- glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002;68:84-90
26. Yoon KH, Wong A, Shakespeare T, Sivalingham P. High prevalence of the antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003;12:112-116
27. Gomez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35:322-332
28. Miesbach W, Scharrer I, Asherson RA. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006;25:840-844
29. Miesbach W, Scharrer I, Asherson RA. High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma. Clin Rheumatol 2007;26:95-97
30. Schved JF, Dupuy-Fons C, Biron C, et al. A prospective epdimiological study of the occurrence of antiphospholipid antibody; the Montpelier Antiphospholipid (MAP) Study. Haemostasis 1994;24:175-182
31. Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome-Asherson's syndrome. Ann Med Interne (Paris) 2003;154:195-196
32. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-512
33. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa M-C, Piett JC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-534
34. Miesbach W, Asherson RA, Cervera R, et al. The role of malignancies in patients with catastrophic antiphospholipid (Asherson's) syndrome. Clin Rheumatol 2007;26:2109-2114
35. Cervera R, Asherson RA, Acevedo ML, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004;63:1312-1317
36. Cervera R, Espinosa G, Bucciarelli S, Gomez-Puerta JA, Font J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Dev 2006;6:81-84
37. Amital H, Levy Y, Davidson C, et al. Catastrophic antiphospholipid syndrome: remission following leg amputation in two cases. Semin Arthritis Rheum 2001;31:127-132
38. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
39. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952
40. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735